Navigation Links
Genomatica Produces Pure BDO From Natural Sugars
Date:6/2/2009

With downstream processing techniques proven cost-effective, Genomatica looks to develop demonstration plant

SAN DIEGO, June 2 /PRNewswire/ -- Genomatica, a sustainable chemicals company, announced today that the company's engineering team has achieved an important milestone toward the production of commercial grade 1,4-butanediol (BDO) from renewable feedstocks using Genomatica's novel bioprocess. The company has demonstrated that it can process BDO produced from sugar to greater than 99 percent purity using a proprietary and cost-effective recovery process. The achievement clears the way for development of a demonstration facility to begin operating next year.

The new process begins with producing BDO in fermentation broths generated by microbes engineered to directly produce BDO from sugars, and uses process designs and equipment compatible with large-scale chemical production. The purification achievement proves the feasibility of critical downstream process engineering elements of Genomatica's manufacturing method for renewable BDO. Fully integrated, the process will offer Genomatica's partners a competitive advantage relative to producers that today generate BDO entirely from fossil fuels.

"The first 100-percent renewably sourced and purified BDO - it's a powerful sight that symbolizes the transformation that is possible for our industry," said Christophe Schilling, chief executive officer of Genomatica. "With a cost advantage over traditional manufacturing processes, our bio-manufacturing method for BDO will release chemical producers from the fluctuations of the hydrocarbon markets and lower their overall carbon footprint, while meeting the growing demand for sustainably manufactured products."

When Genomatica began development of this breakthrough bio-manufacturing process, the company set three key laboratory-scale development milestones to commercialize the process: first, to
'/>"/>

SOURCE Genomatica
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. New Genomatica Chemical Process Targets Ailing Ethanol Assets
2. New small-scale generator produces alternating current by stretching zinc oxide wires
3. High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkins Lymphoma
4. PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average
5. Pioneering IVF Technique Produces Region's First Pregnancy
6. New technique produces genetically identical stem cells
7. Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkins Lymphoma
8. CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
9. Anthrax vaccine produces immunity with nanoparticles, not needles
10. Anthrax vaccine produces immunity with nanoparticles, not needles
11. Cancer Fighting Nutrition Supplement, Caplex, Offers Cancer Patients A New All-Natural Treatment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... , April 23, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... report its first quarter 2015 results before the Nasdaq ... then host a live conference call and webcast to discuss ... morning, April 30, 2015 at 8:00 a.m. Eastern Time ... the live conference call by dialing 866-952-1906 (US) or ...
(Date:4/23/2015)... FRANCISCO, Calif. , April 23, 2015  Veracyte, Inc. ... entered into a definitive agreement to sell approximately $40 ... Under the agreement, the investors will purchase an aggregate ... price of $8.15 per share, the closing stock price ... by new and existing investors, including Broadfin Capital, Camber ...
(Date:4/23/2015)... HOUSTON , April 23, 2015  Metanome, ... today announced the company has changed its name ... reflect Diversigen,s positioning as the single commercial source ... need to capitalize on the diverse opportunities of ... types that Diversigen accepts – including those that ...
(Date:4/23/2015)... Delpor, Inc. (Delpor), a biotechnology company ... States Patent and Trademark Office has issued 2 new ... US Pat. No. 8,986,727 was issued on March ... device for the sustained release of therapeutic agents. ... sustained (zero-order) release of large and small molecules for ...
Breaking Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4Metanome Announces Corporate Name Change to Diversigen 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3
... June 2 NeoGenomics, Inc. (OTC Bulletin ... Sixth Annual Noble Financial Equity Conference at 12:30 PM ... the Seminole Hard Rock Hotel in Hollywood, FL. ... give a presentation regarding NeoGenomics, market positioning, financial performance, and ...
... Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today announced the Company,s participation at two ... , , EVP ... SMID Cap Conference at the InterContinental Hotel in Boston, Mass. beginning at ... , , ...
... to be effective in making silicon-based electronics may be viable ... molecule thick. Researchers at the Max Plank Institute for Metals ... online in the journal Physical Review B on June 1. ... the basis for a host of extremely small and efficient ...
Cached Biology Technology:NeoGenomics to Present at Noble Financial's 6th Annual Equity Conference on Monday, June 7th 2NeoGenomics to Present at Noble Financial's 6th Annual Equity Conference on Monday, June 7th 3Genoptix Announces Participation at June Investor Conferences 2
(Date:4/2/2015)... BETHESDA, Md. , April 2, 2015 ... Salt Lake City , the American ... election of five new directors to its Board.  Members ... for the ACMG and for forming and advancing its ... the medical genetics profession. "It,s an eventful ...
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
(Date:3/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has ... Global Strategic Business Report" report to their offering. ... in US$ Thousands by the following Segments: Face Biometrics, and Voice ... Canada , Japan , ... East & Africa , and ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... that have died in mass strandings in New Zealand ... a new study concludes, challenging a popular assumption that ... almost certain death because of familial ties. Using ... determined that both related and unrelated individuals were scattered ...
... , Francisella tularensis , the cause of tularemia ... considered a potential biological weapon because it is readily aerosolized ... humans. While a live attenuated vaccine strain has been ... understand the basis for its attenuated virulence. In an ...
... engineers are developing the right mix to reduce concrete,s ... biofuel byproducts. "The idea is to use bioethanol ... concrete as a partial replacement of cement," said Feraidon ... using these materials we can reduce the carbon footprint ...
Cached Biology News:Study questions the role of kinship in mass strandings of pilot whales 2Study questions the role of kinship in mass strandings of pilot whales 3News tips from the journal mBio®, volume 4, issue 1 2Researchers building stronger, greener concrete with biofuel byproducts 2Researchers building stronger, greener concrete with biofuel byproducts 3
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
Biology Products: